CD274 and non-small cell lung carcinoma: Given the lack of a secure PD-L1-expression-based clinical stratification of patients as responders versus non-responders, NSCLC patients can be offered PD-1/PD-L1 immunotherapy irrespective of their PD-L1 TPS.